Lifecore Biomedical, Inc. (LFCR)

NASDAQ: LFCR · IEX Real-Time Price · USD
8.04
+0.14 (1.77%)
Dec 6, 2022 4:00 PM EST - Market closed
1.77%
Market Cap 239.34M
Revenue (ttm) 273.55M
Net Income (ttm) -100.02M
Shares Out 29.58M
EPS (ttm) -3.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 105,852
Open 7.85
Previous Close 7.9
Day's Range 7.81 - 8.1
52-Week Range 7.81 - 12.04
Beta 1.06
Analysts Buy
Price Target 14.03 (+74.5%)
Earnings Date Jan 4, 2023

About LFCR

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology developm... [Read more]

Industry Drug Manufacturers-Specialty & Generic
Founded 1986
CEO Albert Bolles
Employees 689
Stock Exchange NASDAQ
Ticker Symbol LFCR
Full Company Profile

Financial Performance

In 2022, LFCR's revenue was $185.79 million, an increase of 8.30% compared to the previous year's $171.55 million. Losses were -$97.43 million, 198.3% more than in 2021.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for LFCR stock is "Buy." The 12-month stock price forecast is 14.03, which is an increase of 74.50% from the latest price.

Price Target
$14.03
(74.50% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Lifecore Biomedical Raises Capital for Growth with Existing Stockholder

Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced the closing of a $5 million private placement (“...

1 week ago - GlobeNewsWire